Involved in SBIR intheirown right for about one year (2008-2009) Luminex Corporation (NASDAQ:LMNX) develops, manufactures, and sells proprietary biological offering xMAP technology, an open architecture and multiplexing technology, a capability that allows simultaneous analysis of up to100 bioassays. Headquartered in Auston TX but with a presnece and faciiies in several other US cities and overseas, the company's technology is used in various segments of the life sciences industry, to include the fields of drug discovery and development, clinical diagnostics, genetic analysis, bio-defense, protein analysis, and biomedical research. Serving pharmaceutical companies, clinical laboratories, research institutions, and medical institutions. Most recently Luminex's efforts have included Covid 19 testing. In April 2021 it was announced that the Italian company DiaSorin would buy Luminex for $1.8 Billion
